Clinical Trial Results:
MINeralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-Elevation Myocardial Infarction(STEMI).
Summary
|
|
EudraCT number |
2013-001069-18 |
Trial protocol |
GB |
Global end of trial date |
04 Apr 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Aug 2017
|
First version publication date |
24 Aug 2017
|
Other versions |
|
Summary report(s) |
Trial design paper |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
12/0533
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
EudraCT number: 2013-001069-18 | ||
Sponsors
|
|||
Sponsor organisation name |
University College London
|
||
Sponsor organisation address |
149 Tottenham Court Road, London, United Kingdom, London W1T 7DN
|
||
Public contact |
Derek Hausenloy, Hatter Cardiovascular Institute, +44 203 447 9894, d.hausenloy@ucl.ac.uk
|
||
Scientific contact |
Derek Hausenloy, Hatter Cardiovascular Institute, +44 203 447 9894, d.hausenloy@ucl.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Aug 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
04 Apr 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
04 Apr 2016
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
Does the administration of mineralo-corticoid-receptor antagonist (MRA) therapy initiated prior to coronary angioplasty followed by three months MRA therapy reduced the damage to the heart muscle in patients presenting with a heart attack?
|
||
Protection of trial subjects |
No applicable
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jul 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 70
|
||
Worldwide total number of subjects |
70
|
||
EEA total number of subjects |
70
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
42
|
||
From 65 to 84 years |
28
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
111 patients gave initial consent and 70 patients were enrolled in the study. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
951 patients were screened between November 2013 and January 2016 | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Nov 2013 to Jan 2016 (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Double blind | ||||||||||||
Roles blinded |
Subject, Investigator, Data analyst | ||||||||||||
Blinding implementation details |
Eligible patients were randomised by the unblinded study investigator to Aldactone® canrenoate treatment or placebo immediately after the diagnostic coronary angiography. Randomisation was done on a web-based service through www.SealedEnvelope.com. The study team member collecting the data at each study site remained blinded to the allocation of patients to either intervention or placebo.
|
||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
Intervention arm | ||||||||||||
Arm description |
one single bolus i.v. Aldactone® canrenoate 200 mg prior to reopening of the infarcted artery followed by 25 mg spironolactone oral, daily for 3 months. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Aldactone canrenoate
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||
Routes of administration |
Intravenous bolus use
|
||||||||||||
Dosage and administration details |
Aldactone® canrenoate 200 mg prior to reopening of the infarcted artery followed by 3 months of oral spironolactone 25 mg
|
||||||||||||
Arm title
|
Placebo | ||||||||||||
Arm description |
10 ml normal saline drawn-up into an identical opaque syringe given as a bolus over 2 minutes. | ||||||||||||
Arm type |
Placebo | ||||||||||||
Investigational medicinal product name |
Normal saline
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
The placebo was 10 ml normal saline drawn-up into an identical opaquesyringe given as a bolus over 2 minutes, prior to PPCI
|
||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nov 2013 to Jan 2016
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intervention arm
|
||
Reporting group description |
one single bolus i.v. Aldactone® canrenoate 200 mg prior to reopening of the infarcted artery followed by 25 mg spironolactone oral, daily for 3 months. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
10 ml normal saline drawn-up into an identical opaque syringe given as a bolus over 2 minutes. |
|
|||||||||||||
End point title |
Chronic infarct size by CMR | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
3 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary outcome analysis | ||||||||||||
Statistical analysis description |
The primary endpoint (myocardial infarct (MI) size in grams at 12 weeks) was compared between those randomised to placebo and those randomised to mineralocorticoid receptor antagonist therapy (MRA) using linear regression with the myocardial infarct size at three months as the response variable and the treatment group included as a binary covariate in the model. The distribution of MI size in grams showed marked positive skew, but this distribution was normalised by expressing MI size as % of LV
|
||||||||||||
Comparison groups |
Placebo v Intervention arm
|
||||||||||||
Number of subjects included in analysis |
70
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Acute MI size by CMR | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Within the first week.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Microvascular obstruction | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
One week
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in end-diastolic volume at 3 months | ||||||||||||
End point description |
Change in LV end-diastolic at 3 months
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
3 months
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in end-systolic volume at 3 months | ||||||||||||
End point description |
Cchange in end-systolic volume at 3 months
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
3 months
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
November 2015 to April 2016
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Less than 5% of non-serious adverse events recorded. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Apr 2016 |
Change in trial statistician which led to a change in statistical plan. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |